Stoneprime US

The principal activity of Stoneprime US is investing in the biotechnology sector, combining finance, biotechnology and artificial intelligence. The company develops qualitative and quantitative AI algorithms to automate scientific analysis and assess the development potential of publicly traded biotech companies in the United States.

Stoneprime US offers investment solutions based on predictive analysis of FDA approval for new drugs, using AI to anticipate market reactions to scientific discoveries. The products and services are primarily aimed at institutional investors, high-net-worth individuals, family offices and venture capital funds wishing to invest in the biotech sector with an innovative, AI-based approach.